Edward Tenthoff
Stock Analyst at Piper Sandler
(2.38)
# 2,585
Out of 5,050 analysts
181
Total ratings
41.95%
Success rate
-0.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $442.70 | +10.46% | 15 | Oct 31, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $13 → $16 | $7.63 | +109.70% | 5 | Oct 30, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $5.16 | +132.56% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $4.25 | +182.35% | 2 | Sep 15, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $8.96 | +67.41% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $2.12 | +135.85% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $55.12 | +90.49% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.82 | +145.01% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.37 | +410.95% | 1 | Jun 3, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $10.63 | +31.70% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.53 | +273.97% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $18.36 | +161.44% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $14.61 | +64.27% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $31.80 | +145.28% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $13.90 | +115.83% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $39.23 | +14.71% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $24.54 | +181.17% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $9.52 | +582.77% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $5.93 | +490.22% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.53 | +1,207.19% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.34 | +123.88% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.70 | +327.84% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $12.31 | +29.98% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.07 | +460.75% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.71 | +192.40% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $58.83 | -4.81% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $28.86 | +759.32% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.71 | +2,325.88% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $14.02 | +1,183.88% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.50 | +151.43% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $6.44 | +474.53% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.47 | +44,299,219.73% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $854.65 | -58.58% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.59 | +8,390.57% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $409.47 | -21.12% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $40.81 | -11.79% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $0.86 | +2,790.51% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.28 | +11,618.75% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.44 | +312,825.17% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $657.53 | - | 11 | Feb 13, 2017 |
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $442.70
Upside: +10.46%
Fulcrum Therapeutics
Oct 30, 2025
Reiterates: Overweight
Price Target: $13 → $16
Current: $7.63
Upside: +109.70%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $5.16
Upside: +132.56%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.25
Upside: +182.35%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $8.96
Upside: +67.41%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $2.12
Upside: +135.85%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $55.12
Upside: +90.49%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.82
Upside: +145.01%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.37
Upside: +410.95%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $10.63
Upside: +31.70%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.53
Upside: +273.97%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $18.36
Upside: +161.44%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $14.61
Upside: +64.27%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $31.80
Upside: +145.28%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $13.90
Upside: +115.83%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $39.23
Upside: +14.71%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $24.54
Upside: +181.17%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $9.52
Upside: +582.77%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $5.93
Upside: +490.22%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.53
Upside: +1,207.19%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.34
Upside: +123.88%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.70
Upside: +327.84%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $12.31
Upside: +29.98%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.07
Upside: +460.75%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.71
Upside: +192.40%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $58.83
Upside: -4.81%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $28.86
Upside: +759.32%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.71
Upside: +2,325.88%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $14.02
Upside: +1,183.88%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.50
Upside: +151.43%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $6.44
Upside: +474.53%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.47
Upside: +44,299,219.73%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $854.65
Upside: -58.58%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.59
Upside: +8,390.57%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $409.47
Upside: -21.12%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $40.81
Upside: -11.79%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $0.86
Upside: +2,790.51%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.28
Upside: +11,618.75%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.44
Upside: +312,825.17%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $657.53
Upside: -